Ian Giles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1875121/publications.pdf

Version: 2024-02-01

125	3,426	31	55
papers	citations	h-index	g-index
127	127	127	3773
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeedingâ€"Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1. Rheumatology, 2016, 55, 1693-1697.	1.9	350
2	Randomized Controlled Trial of Rituximab and Costâ€Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2017, 69, 1440-1450.	5.6	194
3	ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Proâ€Inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 Pathway. American Journal of Reproductive Immunology, 2009, 62, 96-111.	1.2	158
4	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human Î ² 2-glycoprotein I: Mutation studies including residues R39 to R43. Arthritis and Rheumatism, 2007, 56, 280-290.	6.7	134
5	BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeedingâ€"Part II: analgesics and other drugs used in rheumatology practice: Table 1. Rheumatology, 2016, 55, 1698-1702.	1.9	129
6	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmunity Reviews, 2015, 14, 153-159.	5.8	106
7	Antibodies to apolipoprotein Aâ€I, highâ€density lipoprotein, and Câ€reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 845-854.	6.7	100
8	Health-related utility values of patients with primary Sj \tilde{A} ¶gren's syndrome and its predictors. Annals of the Rheumatic Diseases, 2014, 73, 1362-1368.	0.9	87
9	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Reviews, 2020, 39, 100610.	5.7	85
10	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology, 2011, 50, 1401-1408.	1.9	81
11	The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. Lupus, 2011, 20, 5-13.	1.6	78
12	Fatigue in primary Sj \tilde{A} ¶gren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open, 2016, 2, e000282.	3.8	77
13	Symptom-based stratification of patients with primary Sj \tilde{A} ¶gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	3.9	76
14	Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. Journal of Rheumatology, 2019, 46, 245-250.	2.0	76
15	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. Journal of Immunology, 2010, 184, 6622-6628.	0.8	67
16	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of Â2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology, 2015, 54, 722-727.	1.9	67
17	Measuring IgA Anti-Î ² 2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. PLoS ONE, 2016, 11, e0156407.	2.5	66
18	Modulation of Trophoblast Angiogenic Factor Secretion by Antiphospholipid Antibodies is Not Reversed by Heparin. American Journal of Reproductive Immunology, 2011, 66, 286-296.	1.2	65

#	Article	IF	CITATIONS
19	United Kingdom Primary Sjogren's Syndrome Registrya united effort to tackle an orphan rheumatic disease. Rheumatology, 2011, 50, 32-39.	1.9	64
20	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology, 2015, 54, 2042-2050.	1.9	61
21	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2012, 71, 1973-1979.	0.9	57
22	Cardiovascular Risk Factors in Women With Primary Sjögren's Syndrome: United Kingdom Primary Sjögren's Syndrome Registry Results. Arthritis Care and Research, 2014, 66, 757-764.	3.4	56
23	Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Seminars in Arthritis and Rheumatism, 2019, 48, 911-920.	3.4	54
24	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce \hat{I}^2 -chemokines. Journal of Experimental Medicine, 2010, 207, 763-776.	8.5	51
25	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. PLoS ONE, 2015, 10, e0143970.	2.5	45
26	Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology, 2010, 49, 392-394.	1.9	44
27	Association between Systemic Lupus Erythematosus and Periodontitis: A Systematic Review and Meta-analysis. Frontiers in Immunology, 2017, 8, 1295.	4.8	44
28	Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with â€~seronegative' antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2015, 74, 317-319.	0.9	42
29	Purified IgG from Patients with Obstetric but not IgG from Nonâ€obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. American Journal of Reproductive Immunology, 2015, 73, 390-401.	1.2	35
30	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatology International, 2019, 39, 1867-1873.	3.0	35
31	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnology, 2006, 6, 8.	3.3	33
32	Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nature Reviews Rheumatology, 2019, 15, 391-402.	8.0	33
33	Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens. Journal of Immunology, 2006, 177, 1729-1736.	0.8	30
34	Antibodies to Serine Proteases in the Antiphospholipid Syndrome. Current Rheumatology Reports, 2010, 12, 45-52.	4.7	30
35	Examining How Antiphospholipid Antibodies Activate Intracellular Signaling Pathways: A Systematic Review. Seminars in Arthritis and Rheumatism, 2012, 41, 720-736.	3.4	30
36	The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients. Rheumatology, 2012, 51, 1877-1880.	1.9	28

#	Article	IF	CITATIONS
37	Pregnancy Outcomes in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2017, 44, 128-129.	2.0	27
38	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. Journal of Autoimmunity, 2018, 93, 114-123.	6.5	24
39	lgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Research and Therapy, 2015, 17, 26.	3.5	23
40	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. Arthritis Research, 2005, 7, R47.	2.0	22
41	Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome?. Lupus, 2009, 18, 671-675.	1.6	22
42	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 72-78.	3.4	22
43	Do the EULAR Sjogren's syndrome outcome measures correlate with health status in primary Sjogren's syndrome?. Rheumatology, 2015, 54, 655-659.	1.9	22
44	Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions. Journal of Immunology, 2009, 182, 4836-4843.	0.8	19
45	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. Blood, 2014, 124, 3808-3816.	1.4	19
46	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology, 2020, 59, 524-533.	1.9	19
47	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. Arthritis Care and Research, 2017, 69, 1714-1723.	3.4	18
48	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. Cell Death and Disease, 2018, 8, e2549-e2549.	6.3	17
49	Evaluating the conformation of recombinant domain I of \hat{I}^2 2-glycoprotein I and its interaction with human monoclonal antibodies. Molecular Immunology, 2011, 49, 56-63.	2.2	16
50	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Research and Therapy, 2015, 17, 47.	3.5	16
51	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. Rheumatology International, 2017, 37, 623-631.	3.0	16
52	Identification of a Novel HIF- $1\hat{l}\pm\hat{l}\pm\hat{M}\hat{l}^2$ 2 Integrin-NET Axis in Fibrotic Interstitial Lung Disease. Frontiers in Immunology, 2020, 11, 2190.	4.8	16
53	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. Molecular Immunology, 2004, 40, 745-758.	2.2	15
54	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. Arthritis and Rheumatism, 2011, 63, 3512-3521.	6.7	15

#	Article	IF	CITATIONS
55	The association between IgG and IgM antibodies against cardiolipin, \hat{l}^2 2-glycoprotein I and Domain I of \hat{l}^2 2-glycoprotein I with disease profile in patients with multiple sclerosis. Molecular Immunology, 2016, 75, 161-167.	2.2	14
56	PECylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2018, 9, 2413.	4.8	14
57	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. RMD Open, 2019, 5, e000885.	3.8	14
58	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. Rheumatology, 2020, 59, 146-152.	1.9	14
59	â€^A new dawn of anticoagulation for patients with antiphospholipid syndrome?'. Lupus, 2012, 21, 1263-1265.	1.6	13
60	Autoimmune rheumatic disease IgG has differential effects upon neutrophil integrin activation that is modulated by the endothelium. Scientific Reports, 2019, 9, 1283.	3.3	13
61	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis and Rheumatism, 2007, 56, 2392-2401.	6.7	12
62	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. Rheumatology Advances in Practice, 2018, 2, rky003.	0.7	11
63	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. Frontiers in Immunology, 2018, 9, 2244.	4.8	11
64	Real benefits of ultrasound evaluation of hand and foot synovitis for better characterisation of the disease activity in rheumatoid arthritis. European Radiology, 2019, 29, 6345-6354.	4.5	11
65	A systematic review of live vaccine outcomes in infants exposed toÂbiologic disease modifying anti-rheumatic drugs <i>in utero</i> . Rheumatology, 2022, 61, 3902-3906.	1.9	10
66	How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Practice and Research in Clinical Rheumatology, 2009, 23, 525-537.	3.3	9
67	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology, 2015, 55, kev373.	1.9	9
68	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. Lancet Rheumatology, The, 2021, 3, e9-e10.	3.9	9
69	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. BMC Biotechnology, 2015, 15, 104.	3.3	8
70	Oxidation of \hat{I}^2 -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. PLoS ONE, 2017, 12, e0186513.	2.5	8
71	A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease. Expert Review of Clinical Immunology, 2020, 16, 321-333.	3.0	8
72	Mechanisms determining the amelioration of rheumatoid arthritis in pregnancy: A systematic review. Seminars in Arthritis and Rheumatism, 2020, 50, 1357-1369.	3.4	8

#	Article	IF	CITATIONS
73	Poor adherence to guidelines on early management of acute hot swollen joint(s): an evaluation of clinical practice and implications for training. International Journal of Clinical Practice, 2015, 69, 618-622.	1.7	7
74	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. Scientific Reports, 2017, 7, 10788.	3.3	7
75	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. Swiss Medical Weekly, 2018, 148, w14588.	1.6	7
76	Fertility and pregnancy in systemic lupus erythematosus. Indian Journal of Rheumatology, 2016, 11, 128.	0.4	6
77	Laboratory Tests for the Antiphospholipid Syndrome. Methods in Molecular Biology, 2014, 1134, 221-235.	0.9	5
78	Prescribing anti-rheumatic drugs in pregnancy and breastfeedingâ€"the British Society for Rheumatology guideline scope. Rheumatology, 2021, 60, 3565-3569.	1.9	5
79	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. Arthritis Research and Therapy, 2014, 16, R48.	3.5	4
80	Do Antiphospholipid Antibodies Have Direct Pathologic Effects Upon Endometrial and Trophoblast Cells?. Current Rheumatology Reviews, 2009, 5, 83-97.	0.8	4
81	Use of monoclonal antibodies to dissect specificity and pathogenesis of antiphospholipid antibodies. Lupus, 2010, 19, 359-364.	1.6	3
82	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity., 2017,, 117-143.		3
83	Pathogenesis of Antiphospholipid Antibody Syndrome. , 2019, , 324-337.		3
84	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. Lancet Rheumatology, The, 2020, 2, e735-e736.	3.9	3
85	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
86	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests., 2017,, 171-187.		3
87	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. Current Rheumatology Reviews, 2008, 4, 2-11.	0.8	2
88	O26. Does Inflammatory Arthritis Really Improve During Pregnancy? A Systematic Review and Meta-Analysis. Rheumatology, 2014, 53, i40-i40.	1.9	2
89	132â€f Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. Rheumatology, 2018, 57, .	1.9	2
90	Domain I of \hat{I}^2 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in \hat{A} vitro: an effect enhanced by PEGylation. Lupus, 2019, 28, 893-897.	1.6	2

#	Article	IF	CITATIONS
91	O22â€fEvaluating the impact of COVID-19 on patient access to rheumatology services, medication and future care: a nationwide study of more than 2,000 patients. Rheumatology, 2021, 60, .	1.9	2
92	A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy. Seminars in Arthritis and Rheumatism, 2021, 51, 1205-1217.	3.4	2
93	A systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy. Clinical Medicine, 2020, 20, s98-s98.	1.9	2
94	138.â€ f How Acceptable is Ovarian Protection to Woman of Childbearing Age Treated with Cyclophosphamide: Experience at a Single Centre. Rheumatology, 2015, , .	1.9	1
95	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
96	063â€fReal-life benefits of ultrasound evaluation of hand and foot synovitis and lack of correlation with DAS-28 in rheumatoid arthritis. Rheumatology, 2019, 58, .	1.9	1
97	P116 $\hat{a} \in f$ A systematic review of the safety of non-tumour necrosis factor inhibitor and targeted synthetic drugs in rheumatic disease in pregnancy. Rheumatology, 2020, 59, .	1.9	1
98	P202â€fAdministering live vaccines to infants exposed to biologic and targeted synthetic DMARDs in-utero for maternal treatment of rheumatic disease: a systematic review of the literature. Rheumatology, 2021, 60, .	1.9	1
99	Update on Use of Biologic and Targeted Synthetic Drugs in Pregnancy. , 2020, , 77-92.		1
100	Wrist joint aspiration. British Journal of Hospital Medicine (London, England: 2005), 2012, 73, C2-C4.	0.5	0
101	O59.â€fThe Cellular Effects of Anti-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome are Inhibited by Factor Xa Inhibitors, Hydroxychloroquine and Fluvastatin. Rheumatology, 2014, 53, i56-i56.	1.9	O
102	144.â€fTo Aspirate or Not to Aspirate: A Trainee Doctor's Dilemma. Rheumatology, 2014, 53, i114-i114.	1.9	0
103	324.â€fFactor-Xa-Reactive Antibodies in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome Have Differential Effects on Coagulation Assays. Rheumatology, 2014, 53, i181-i181.	1.9	O
104	139â€fA Single-Centre Experience of the Issues Discussed During Pre-Pregnancy Counselling of Patients with Inflammatory Rheumatic Disease. Rheumatology, 0, , .	1.9	0
105	236.â€fHYPOXIA MODULATES NEUTROPHIL INTEGRIN EXPRESSION AND ACTIVATION. Rheumatology, 2017, 56,	. 1.9	O
106	239. PEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL. Rheumatology, 2017, 56, .	1.9	O
107	240.â€ f AUTOIMMUNE RHEUMATIC DISEASE IMMUNOGLOBULIN G DIFFERENTIALLY REGULATES NEUTROPHIL INTEGRIN ACTIVATION AND NEUTROPHIL ACTIVATION. Rheumatology, 2017, 56, .	1.9	O
108	126â€fCross sectional validation of BILAG2004-Pregnancy Index. Rheumatology, 2018, 57, .	1.9	0

#	Article	IF	Citations
109	$252 \hat{a} \in f$ Examining the modulatory effects of anti-serine protease antibodies upon factor Xa, thrombin and complement interactions. Rheumatology, 2018, 57, .	1.9	0
110	O21â€fBILAG2004-Pregnancy index is sensitive to change. Rheumatology, 2018, 57, .	1.9	0
111	$037\hat{a} \in f$ A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone analogues in women of child-bearing age with autoimmune rheumatic disease. Rheumatology, 2019, 58, .	1.9	O
112	022â€fBoth Domain I and PEGylated Domain I of Beta-2-Glycoprotein I (β2GPI) are capable of inhibiting IgA APS antibody binding. Rheumatology, 2019, 58, .	1.9	0
113	090â€f Mechanisms determining disease activity of rheumatoid arthritis in pregnancy: a systematic review. Rheumatology, 2019, 58, .	1.9	0
114	IO65â€fConsidering fertility: do women (or men) with rheumatic disease have fewer children?. Rheumatology, 2019, 58, .	1.9	0
115	019â€∱Modulation of monocyte autophagy as a therapeutic target in antiphospholipid syndrome. Rheumatology, 2019, 58, .	1.9	O
116	OP0044â€A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE GONADOTOXIC EFFECTS OF CYCLOPHOSPHAMIDE AND BENEFITS OF GONADOTROPIN RELEASING HORMONE ANALOGUES IN WOMEN OF CHILD-BEARING AGE WITH AUTOIMMUNE RHEUMATIC DISEASE. , 2019, , .		0
117	EP31â€fMusculoskeletal ultrasound of rheumatoid arthritis pregnancy: a single centre experience. Rheumatology, 2020, 59, .	1.9	0
118	P172 Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. Rheumatology, 2020, 59, .	1.9	0
119	P31â€Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. , 2020, , .		0
120	Ensuring high standards of British Society for Rheumatology clinical guidelines: reflections from the coalface. Rheumatology, 2021, 60, 2497-2499.	1.9	0
121	P065â€fThe road to recovery: developing a new service for urgent face-to-face rheumatology outpatient appointments during the COVID-19 pandemic: a single centre experience. Rheumatology, 2021, 60, .	1.9	O
122	A career in rheumatology. BMJ: British Medical Journal, 2003, 326, 157Sa-157.	2.3	0
123	Play attention! Therapeutic aspects to play in delirium prevention and management. Wellcome Open Research, 2020, 5, 277.	1.8	0
124	Haemophagocytic lymphohistiocytosis in pregnancy. Clinical Medicine, 2021, 21, e682.2-e683.	1.9	0
125	Postpartum venous thromboprophylaxis needs to be stratified in inflammatory diseases. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, , .	2.3	O